Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Investing in a Purchased Company

It's fun to see what companies professional investors are interested in. Fortunately, courtesy of the Securities and Exchange Commission, it's not that hard to take a peek at their holdings.

Earlier this week, billionaire investor Steven A. Cohen reported that, through his hedge fund, SAC Capital Advisors, and associated entities, he has upped his stake in Pharmion (Nasdaq: PHRM  ) to 7.1%.

His previous SEC declaration in March said that Cohen owned a 5.1% stake in the company. It isn't clear how long he's owned the additional shares, so it's possible that he and the other hedge fund investors made a ton of cash, since Pharmion has more than doubled since then.

Much of that increase was because Celgene (Nasdaq: CELG  ) announced last month it was acquiring Pharmion for $2.9 billion. Of course, positive trial results for its Vidaza drug back in August helped a lot, too.

Perhaps more interesting than the fact that Cohen increased his ownership is that he made a 13-D filing, the form used by active investors, which varied from the form for passive investors used last March. The most recent filing did say that the purchases were made as an investment and not to influence the company's direction.

Still, with the close of the purchase not happening until later next year, it'll be interesting if Cohen tries to influence the deal to get more money out of Celgene or perhaps another buyer. One has to wonder if Eisai's recent acquisition of MGI Pharma (Nasdaq: MOGN  ) -- one of Pharmion's competitors -- had anything to do with the decision to add to its position.

Frankly, though, I'd look elsewhere than Pharmion, as there are plenty of good bets for biotech in 2008.

For related Foolishness:

As Foolanthropy enters its second decade, join us in working to bring financial education to the world's children. Learn more about Foolanthropy's new direction.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 557483, ~/Articles/ArticleHandler.aspx, 10/28/2016 7:42:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,161.19 -8.49 -0.05%
S&P 500 2,126.41 -6.63 -0.31%
NASD 5,190.10 -25.87 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 4:00 PM
CELG $103.90 Down -0.82 -0.78%
Celgene CAPS Rating: *****